DIEBOLD NIXDORF INC (DBD)       2.29  +0.06 (+2.69%)

2.29  +0.06 (+2.69%)

US2536511031 - Common Stock - After market: 2.29 0 (0%)


Fundamental Rating

2

Taking everything into account, DBD scores 2 out of 10 in our fundamental rating. DBD was compared to 35 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has a bad profitability rating. Also its financial health evaluation is rather negative. DBD has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

1

The profitability ratios for DBD are negative, so there is not much use analyzing them.
DBD has a Return On Assets of -16.18%. This is below the industry average of 2.00%.

DBD's Profit Margin of -13.25% is worse than the rest of the industry. The industry average Profit Margin is 1.84%.
DBD has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of DBD.
VS Industry

ROA (-16.18%) VS Industry: 21% outperformed.

-103.63
43.20

Profit Margin (-13.25%) VS Industry: 21% outperformed.

-1,158.58
38.86

Valuation

Valuation Rating

2

The Forward Price/Earnings Ratio of 1.71 indicates a rather cheap valuation of DBD.
DBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

When comparing the Enterprise Value to EBITDA ratio of DBD to the average industry ratio of 8.52, DBD is valued more expensive than its industry peers. 80% of the companies listed in the same industry are valued cheaper.
VS Industry

Enterprise Value/ EBITDA (13.74) VS Industry: 20% outperformed.

185.12
0.02

Growth

Growth Rating

3

DBD is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 47.07% yearly.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Measured over the past 5 years, DBD shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.35% on average per year.
DBD shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 3.32% yearly.

The Revenue is expected to decrease by -0.07% on average over the next 5 years.
The earnings per share for DBD have decreased strongly by -210.26% in the last year.
The Revenue for DBD has decreased by -10.12% in the past year. This is quite bad
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-5.35% N/A -210.26% -154.97% 30.28% 18.76% 47.07%
Revenue3.32% -5.16% -10.12% -10.66% -2.42% -0.71% -0.07%

Health

Health Rating

1

The Debt to Equity ratio of DBD is in line with the industry averages.
A Current Ratio of 0.43 indicates that DBD may have some problems paying its short term obligations.
When comparing the Current Ratio of DBD to the average industry Current Ratio of 1.83, DBD is less able to pay its short term obligations than its industry peers. 100% of its industry peers have a better Current Ratio.
DBD has a Quick Ratio of 0.43. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.

Compared to an average industry Quick Ratio of 1.19, DBD is worse placed to pay its short term obligations than its industry peers. 100% of its industry peers have a better Quick Ratio.
DBD has an Altman-Z score of -0.22. This is a bad value and indicates that DBD is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 2.36, DBD is in worse financial state than most of its industry peers. 87% of its industry peers have a better Altman-Z score.
DBD has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of DBD.
VS Industry

Debt/Equity (0) VS Industry: 53% outperformed.

3.63
0.00

Quick Ratio (0.26) VS Industry: 0% outperformed.

0.26
36.24

Current Ratio (0.43) VS Industry: 0% outperformed.

0.43
36.70

Altman-Z (-0.22) VS Industry: 13% outperformed.

-10.33
19.02

Dividend

Dividend Rating

0

DBD does not give a dividend.

DBD Daily chart

DIEBOLD NIXDORF INC2.29

NYSE:DBD (11/25/2022, 6:53:41 PM)+0.06 (+2.69%)

After market: 2.29 0 (0%)

Chartmill FA Rating
GICS Sector Information Technology
GICS IndustryGroup Technology Hardware & Equipment
GICS Industry Technology Hardware, Storage & Peripherals
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) 02-08 2023-02-08
Ins Owners 5.43% Inst Owners 75.61%
Market Cap 181.09M Analysts 51.67
Valuation
PE N/A Fwd PE 1.71
PEG (NY) N/A PEG (5Y) N/A
P/S 0.05 P/B N/A
EV/EBITDA 13.74
Dividend
Dividend Yield N/A Dividend Growth N/A
DP 0% Ex-Date N/A
Growth
EPS 1Y -210.26% EPS 3Y N/A
EPS 5Y -5.35% EPS growth Q2Q -135.29%
EPS Next Y -154.97% EPS Next 2Y 30.28%
EPS Next 3Y 18.76% EPS Next 5Y 47.07%
Revenue growth 1Y -10.12% Revenue growth 3Y -5.16%
Revenue growth 5Y 3.32% Revenue growth Q2Q -15.42%
Revenue Next Year -10.66% Revenue Next 2Y -2.42%
Revenue Next 3Y -0.71% Revenue Next 5Y -0.07%
Health
Current Ratio 0.43 Quick Ratio 0.26
Altman-Z -0.22 F-Score 3
Debt/Equity 0 WACC 8.08%
ROIC/WACC N/A
Profitability
ROA -16.18% ROE N/A
ROICexgc N/A ROIC N/A
PM -13.25% OM 1.39%
Asset Turnover 1.22

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA